Sign in and upgrade to a paid plan to export financials as CSV.

Shree Ganesh Biotech (India) Limited

Healthcare · Pharmaceuticals & Biotechnology

BSE: 539470
₹0.47
▼ -0.01 (-2.08%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
40/100
Moderate
Valuation
100/100
Undervalued
Momentum
45/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹19 Cr
PE (TTM)
Data unavailable.
Price to Book
0.3
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-54.8
Free Cash Flow
₹-8 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-200.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-180.04%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-72.57%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-275.23%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
3.32%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
70.22
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
1671.00
as of Sept. 30, 2025
Industry median 10.58 (182 companies)
Net Margin
-40.07%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-40.07%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-6.68%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-1.18%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-1.18%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-1.18%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • No Return on equity is 15% or more (-1.2%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

1 of 2 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 5 met
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.1%
Low 0.4700 · High 0.4900
1W return
-2.1%
Low 0.4600 · High 0.4900
1M return
-6.0%
Low 0.4600 · High 0.5200
52W return
-54.8%
Low 0.4600 · High 0.5500
Lifetime High ₹479.8000 (April 24, 2018)
Lifetime Low ₹0.4600 (Sept. 17, 2026)

Full price history and technicals →

EMA & SMA

Bullish0
Bearish6
5D
0.5
10D
0.5
20D
0.5
50D
0.6
100D
0.8
200D
1.1

Delivery and volume

Day avg. delivery
64.9%
Week avg. delivery
69.7%
Month avg. delivery
67.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

0.48
Pivot
First resistance0.48
Second resistance0.50
Third resistance0.50
First support0.46
Second support0.46
Third support0.44
Day RSI33.5
Day MFI37.6
Day MACD-0.04
Day MACD signal-0.05

Beta

1M0.37
3M0.11
1Y0.11
3Y0.46

Price change analysis

↓ -6.0%
Over 1 Month
LowHigh
0.460.52
↓ -54.8%
Over 3 Months
LowHigh
0.460.55
↓ -54.8%
Over 6 Months
LowHigh
0.460.55
↓ -54.8%
Over 1 Year
LowHigh
0.460.55
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Revenue (June 30, 2026)
₹1 Cr
Net profit (June 30, 2026)
₹-1 Cr
Basic EPS (June 30, 2026)
₹-0.0100

Ranks #165 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • FII/FPI1.42%

Largest holders

Data unavailable.

Historical fii holding

FII/FPI holdings were unchanged at 1.42% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
27 Mar 2024 NEW ERA FUND LIMITED Bulk Sell 3,000,000 1.1000 BSE
8 Jan 2024 TOPGAIN FINANCE PRIVATE LIMITED Bulk Buy 500,000 1.4700 BSE
8 Jan 2024 TOPGAIN FINANCE PRIVATE LIMITED Bulk Sell 2,958,016 1.4700 BSE
5 Jan 2024 TOPGAIN FINANCE PRIVATE LIMITED Bulk Sell 8,637,984 1.5600 BSE
4 Jan 2024 SETU SECURITIES PVT. LTD. Bulk Buy 2,568,661 1.4800 BSE
4 Jan 2024 SHRI CHAND Bulk Sell 3,012,000 1.4800 BSE
4 Jan 2024 TOPGAIN FINANCE PRIVATE LIMITED Bulk Buy 11,596,000 1.4900 BSE
20 Dec 2023 ASHOK KUMAR Bulk Buy 4,410,000 1.3300 BSE
14 Dec 2023 SHRI CHAND Bulk Buy 2,660,000 1.1400 BSE
14 Dec 2023 NATTAYA CHOWDHURY Bulk Sell 6,000,000 1.1100 BSE

All bulk and block deals →

Corporate Announcements

All 3 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
28 Sep 2026 AGM/EGM Shree Ganesh Biotech (India) Ltd - 539470 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
28 Sep 2026 AGM/EGM Shree Ganesh Biotech (India) Ltd - 539470 - Shareholder Meeting / Postal Ballot-Outcome of AGM
3 Sep 2026 Corp. Action Shree Ganesh Biotech (India) Ltd - 539470 - Intimation Of Book Closure Pursuant To Regulation 42 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (1671.0x)

Weaknesses

  • Low Return on Equity (-1.2%)
  • Thin net profit margin (-40.1%)
  • Declining profit YoY (-275.2%)

Opportunities

  • Trading below book value (PB 0.29)

Threats

  • Down 54.8% over the past year

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Shree Ganesh Biotech (India) Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.